Name of Policy: Prevention, Identification and THE UNIVERSITY OF TOLEDO MEDICAL CENTER **Management of Tardive Dyskinesia Policy Number:** 3364-160-SD-131 **Department: Psychiatry** Approving Chief Executive Officer - UTMC Officer: Chair/Medical Director Responsible Agent: Department of Psychiatry Administrative Director Department of Psychiatry **Effective Date:** 01/01/2023 Scope: **OP-Clinic-Psychiatry** Initial Effective Date: 07/2004 New policy proposal Minor/technical revision of existing policy Major revision of existing policy Reaffirmation of existing policy

(A) Policy Statement

Strategies will be used to minimize the risk of tardive dyskinesia (TD) and to identify and treat if it is discovered.

(B) Purpose of Policy

To minimize risk from adverse effects from prolonged use of antipsychotic medications.

(C) Procedure

- 1. Patients will be examined every 3 to 12 months, depending on medication and symptoms, for the appearance of abnormal movements and document findings.
- 2. If patients are noted to have abnormal movements; a differential diagnosis will be considered, including the possibility of TD.
- 3. Findings will be discussed with the patient and/or guardian.
- 4. Patients who have been identified as having symptoms of TD will be:
 - a) Regularly evaluated with standardized scales,
 - b) If clinically feasible, consideration will be given to lowering the dose of the medication or changing the medication to an atypical antipsychotic that is less likely to result in TD and/or other appropriate treatments.

Approved by:		Review/Revision Date: 08/2005 08/2007
/s/	10/19/2022	10/2/2010
Rick Swaine	Date	03/04/2014
Chief Executive Officer - UTMC		01/10/2017
	9/2/2022	11/20/2019
		9/2/2022
/s/		
Cheryl McCullumsmith, MD, PhD	Date	
Chair/Medical Director		
Department of Psychiatry		
/s/	09/02/2022	
Lindsay Watson LSW, MBA		
Administrative Director	2	
Department of Psychiatry		
Review/Revision Completed By: Agency Administration		
		Next Review Date: 9/2/2025